reported solid quarterly performance for the period ended September 30, 2025, with standalone revenue rising to ₹417.29 crore from ₹375.31 crore in the previous quarter. Net profit jumped to ₹30.85 crore compared to ₹21.23 crore sequentially. For H1FY26, the company recorded revenue of ₹792.60 crore and profit of ₹52.08 crore, both higher year-on-year. Operating exclusively in the pharmaceuticals segment, Aarti Pharmalabs continues to expand its global footprint through subsidiaries Aarti USA Inc. and Aarti Pharmachem Ltd., along with a new joint venture with Ganesh Polychem Limited effective April 2025. The Board approved the results in its meeting held on November 9, 2025.

#FundamentalViews

939 likes·43 comments